Sepsis Diagnostics Market Key Players, Share, Trends, Segmentation and Forecast to 2026: Top Players- Danaher, Becton, Dickinson and Company, Roche, Abbott, T2 Biosystems

Market Size - USD 385.0 Million in 2018, Market Growth - CAGR of 9%, Market Trends - Growing awareness and research in diagnosis of Sepsis.

According to the current analysis of Reports and Data, the global Sepsis Diagnostics market was valued at USD 385.0 million in 2018 and is expected to reach USD 772.1 million by the year 2026, at a CAGR of 9.0%. Sepsis is one of the significant challenges faced by hospitals. Sepsis is a medical condition caused by an overactive immune response to an infection.

The immune system releases chemicals for protecting the body from disease; however, excess of these chemicals causes other severe conditions, including inflammation, blood clots, and leaky blood vessels. The unsteady blood flow causes a lack of proper blood flow to all the body organs leading to organ failure and in extreme conditions, septic shock.

Avail the inside scoop of the Sample report @ https://www.reportsanddata.com/sample-enquiry-form/2234

Companies considered and profiled in this market study:
BioM?rieux (France), Danaher (US), Becton, Dickinson and Company (US), Roche (Switzerland), and Abbott (US), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), CytoSorbents (US), and EKF (US)

Sepsis is most common in infants, pregnant women, sick people, and the old population. Thus, a rise in geriatric population has led to an increase in the sepsis diagnosis activities. According to the World Health Organization, Sepsis is estimated to affect 30 million people worldwide every year, leading to the death of at least 6 million people. Growing initiatives taken by the government to increase the awareness related to Sepsissepsis is expected to drive the market growth for Sepsis Diagnostic further. Additionally, a reduction in infant mortality has led to an increase in the number of infants worldwide. This also increases the risk of infants being affected by Sepsissepsis. Sepsis Organization published a report that states, around 6,800 children die every year due to severe Sepsissepsis. Intensive research and increased investments in the development of the healthcare sector is expected to introduce effective treatments for Sepsissepsis and early diagnostic techniques. For instance, MARS-India, an observational study, was conducted to acquire new knowledge that will provide accurate information about the microorganisms and the causes for Sepsissepsis.

Further key findings from the report suggest

o Sepsis Diagnostics market is growing at a CAGR of 9% in Asia Pacific followed by North America and Europe with 8.7 % and 8.8% CAGR respectively. High prevalence of chronic diseases is expected to drive the market growth.

o As of 2018, Blood Culture technology segment dominated Sepsis Diagnostics which holds 37.3% of the global market. North America regional market is the chief revenue generating source for this product segment, followed by Europe and Asia-Pacific regions.

o The market of sepsis diagnostic is driven by the increase in sepsis cases, caused by gram-positive bacteria. The gram-positive bacterium has led to an increase in the number of patients with severe sepsis conditions and septic shock.

o Introduction of new products for diagnostic purposes is expected to majorly drive the market for sepsis diagnosis in the coming years. For example, VIDAS BoRoAoHoMoS PCT, an automated assay measuring procalcitonin (PCT) levels launched by a leading in vitro diagnostic company, BioM?rieux, enables the healthcare professions to take important decisions related to the recommendation of antibiotics for the patient.

o The key players are adopting strategies like partnerships, mergers & acquisitions, expansion and launch of new products. The partnership of Thermo Fisher Scientific and BioM?rieux for improved detection of sepsis with the help of PCT Biomarker is expected to further drive the market for sepsis diagnostics.

Buy Now: https://www.reportsanddata.com/checkout-form/2234

For the purpose of this report, Reports and Data has segmented the Sepsis Diagnostics market on the basis of product type, technology type, pathogens type, method type, test type, end use, and region:

Product Type (Revenue, USD Million; 2016-2026)
o Blood Culture Media
o Assays & Reagents
o Instruments
o Software
o Others

Technology Type (Revenue, USD Million; 2016-2026)
o Microbiology
o Molecular Diagnostics
o Immunoassays
o Flow Cytometry
o Microfluidics
o Biomarkers

Pathogens Type (Revenue, USD Million; 2016-2026)
o Bacterial Sepsis
o Fungal Sepsis
o Others

Method Type (Revenue, USD Million; 2016-2026)
o Conventional Diagnostic
o Automatic Diagnostic

Test Type (Revenue, USD Million; 2016-2026)
o Laboratory Tests
o Point-of-care Tests

End Use (Revenue, USD Million; 2016-2026)
o Hospital
o Clinics
o Others

Regional Outlook (Revenue in USD Million; 2016-2026)
o North America
o Europe
o Asia Pacific
o Middle East & Africa
o Latin America

Read the Comprehensive Report with a meticulous TOC and panoramic coverage of the market: https://www.reportsanddata.com/report-detail/sepsis-diagnostics-market

Contact Us:

John Watson
Head of Business Development
Reports And Data
40 Wall St. 28th floor New York City, NY 10005 United States
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

This release was published on openPR.